
|Articles|January 6, 2005
TAP Pharmaceutical to settle claims, pay $150 million
TAP Pharmaceutical Products agreed to settle claims that consumers and private insurers overpaid for the LHRH hormone analog leuprolide acetate (Lupron), according to a report in The Boston Globe.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Choosing salvage therapy after prostate cancer focal ablation
2
SYNC-T demonstrates high bone metastasis resolution in phase 1 cohort
3
SUO 2025 data confirm IsoPSA accuracy independent of mpMRI use
4
CORE-008: Cretostimogene achieves high CR rate in high-risk NMIBC
5

















